12/8
11:02 am
fulc
Fulcrum Therapeutics (NASDAQ:FULC) had its "underperform" rating reaffirmed by analysts at Citigroup Inc..
Medium
Report
Fulcrum Therapeutics (NASDAQ:FULC) had its "underperform" rating reaffirmed by analysts at Citigroup Inc..
12/8
09:34 am
fulc
Rating for FULC
Medium
Report
Rating for FULC
12/8
09:34 am
fulc
Rating for FULC
Medium
Report
Rating for FULC
12/8
09:25 am
fulc
Rating for FULC
Report
Rating for FULC
12/8
09:14 am
fulc
Fulcrum Therapeutics (NASDAQ:FULC) had its "sector perform" rating reaffirmed by analysts at Royal Bank Of Canada.
Medium
Report
Fulcrum Therapeutics (NASDAQ:FULC) had its "sector perform" rating reaffirmed by analysts at Royal Bank Of Canada.
12/8
09:14 am
fulc
Fulcrum Therapeutics (NASDAQ:FULC) had its "sector perform" rating reaffirmed by analysts at Royal Bank Of Canada.
Medium
Report
Fulcrum Therapeutics (NASDAQ:FULC) had its "sector perform" rating reaffirmed by analysts at Royal Bank Of Canada.
12/8
09:14 am
fulc
Fulcrum Therapeutics (NASDAQ:FULC) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.
Medium
Report
Fulcrum Therapeutics (NASDAQ:FULC) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.
11/24
07:19 am
fulc
Fulcrum Therapeutics (NASDAQ:FULC) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Medium
Report
Fulcrum Therapeutics (NASDAQ:FULC) had its "buy" rating reaffirmed by analysts at HC Wainwright.
10/30
10:57 am
fulc
Rating for FULC
Medium
Report
Rating for FULC
10/30
10:57 am
fulc
Rating for FULC
Medium
Report
Rating for FULC
10/20
08:08 am
fulc
Fulcrum Therapeutics (NASDAQ:FULC) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.
Medium
Report
Fulcrum Therapeutics (NASDAQ:FULC) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.